Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Net Debt Issuances and Repayments: 2018-2022

Historic Net Debt Issuances and Repayments for Autolus Therapeutics (AUTL) over the last 2 years, with Sep 2022 value amounting to $163.1 million.

  • Autolus Therapeutics' Net Debt Issuances and Repayments fell 5.78% to $163.1 million in Q3 2022 from the same period last year, while for Sep 2022 it was $958.4 million, marking a year-over-year increase of 7.90%. This contributed to the annual value of $310.3 million for FY2021, which is N/A change from last year.
  • Per Autolus Therapeutics' latest filing, its Net Debt Issuances and Repayments stood at $163.1 million for Q3 2022, which was down 24.66% from $216.4 million recorded in Q2 2022.
  • In the past 5 years, Autolus Therapeutics' Net Debt Issuances and Repayments ranged from a high of $329.6 million in Q1 2021 and a low of $120.7 million during Q1 2018.
  • Its 2-year average for Net Debt Issuances and Repayments is $243.5 million, with a median of $242.5 million in 2022.
  • Data for Autolus Therapeutics' Net Debt Issuances and Repayments shows a maximum YoY declined of 18.51% (in 2022) over the last 5 years.
  • Quarterly analysis of 3 years shows Autolus Therapeutics' Net Debt Issuances and Repayments stood at $264.9 million in 2018, then reached $310.3 million in 2021, then dropped by 5.78% to $163.1 million in 2022.
  • Its last three reported values are $163.1 million in Q3 2022, $216.4 million for Q2 2022, and $268.6 million during Q1 2022.